UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells

Immunity (Cambridge, Mass.), 2014-12, Vol.41 (6), p.1026-1039

2014

Link zum Volltext

Verfügbarkeit prüfen

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo

The Journal of immunology (1950), 2011-08, Vol.187 (3), p.1113-1119

2011

Link zum Volltext

Verfügbarkeit prüfen

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000413

2020

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms

JCI insight, 2021-12, Vol.6 (24)

2021

Link zum Volltext

Verfügbarkeit prüfen

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells

Nature immunology, 2009-02, Vol.10 (2), p.167-175

2009

Link zum Volltext

Verfügbarkeit prüfen

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and T H -17 cells

Nature immunology, 2009-02, Vol.10 (2), p.167-175

2009

Link zum Volltext

Verfügbarkeit prüfen

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

The Journal of experimental medicine, 2015-09, Vol.212 (10), p.1603-1621

2015

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity

The Journal of immunology (1950), 2012-01, Vol.188 (1), p.155-162

2012

Link zum Volltext

Verfügbarkeit prüfen

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo

The Journal of immunology (1950), 2011-08, Vol.187 (3), p.1097-1105

2011

Link zum Volltext

Verfügbarkeit prüfen

SnapShot: B7/CD28 Costimulation

Cell, 2009-05, Vol.137 (5), p.974-974.e1

2009

Link zum Volltext

Verfügbarkeit prüfen

Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells

Nature immunology, 2010-02, Vol.11 (2), p.109

2010

Link zum Volltext

Verfügbarkeit prüfen

Induction of Regulatory T Cells and Dominant Tolerance by Dendritic Cells Incapable of Full Activation

Journal of Immunology, 2007-07, Vol.179 (2), p.967-976

2007

Link zum Volltext

Verfügbarkeit prüfen

Role of the PD‐1 Pathway in the Immune Response

American journal of transplantation, 2012-10, Vol.12 (10), p.2575-2587

2012

Link zum Volltext

Verfügbarkeit prüfen

Tolerogenicity is not an absolute property of a dendritic cell

European journal of immunology, 2010-06, Vol.40 (6), p.1728-1737

2010

Link zum Volltext

Verfügbarkeit prüfen

Dendritic cell expression of the transcription factor T-bet regulates mast cell progenitor homing to mucosal tissue

The Journal of experimental medicine, 2007-02, Vol.204 (2), p.431-439

2007

Link zum Volltext

Verfügbarkeit prüfen

Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3064-3064

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2196: SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2196-2196

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6639-6639

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4515-4515

2020

Link zum Volltext

Verfügbarkeit prüfen

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Blood, 2018-11, Vol.132 (Supplement 1), p.4393-4393

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

Blood, 2018-11, Vol.132 (Supplement 1), p.339-339

2018

Link zum Volltext

Verfügbarkeit prüfen

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Blood, 2016-12, Vol.128 (22), p.1843-1843

2016

Link zum Volltext

Verfügbarkeit prüfen

Correction: Metastatic breast cancers have reduced immune cell recruitment but harbour increased macrophages relative to their matched primary tumors

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e0755-1corr1

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e0737-3corr1

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(89)

Publikationsform

Sprache

Englisch
(99)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Immunology
(7)
Nature Immunology
(6)
Journal For Immunotherapy Of Cancer
(4)
Nature
(4)
Blood
(3)
Breast Cancer Research And Treatment
(3)
Cancer Research
(3)
Bmc Public Health
(2)
Bmj Open
(2)
Communications Biology
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and T H -17 cells

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo

SnapShot: B7/CD28 Costimulation

Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells

Induction of Regulatory T Cells and Dominant Tolerance by Dendritic Cells Incapable of Full Activation

Role of the PD‐1 Pathway in the Immune Response

Tolerogenicity is not an absolute property of a dendritic cell

Dendritic cell expression of the transcription factor T-bet regulates mast cell progenitor homing to mucosal tissue

Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody

Abstract 2196: SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Correction: Metastatic breast cancers have reduced immune cell recruitment but harbour increased macrophages relative to their matched primary tumors

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Suchergebnisse filtern